Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30801203 | 1.00 | CRBN (0.58) | CRBNDDB1IKZF3BRD4PARP1 | |
| SCHEMBL30903885 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20436991 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL24671242 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF3BRD4PARP1 | |
| SCHEMBL27238859 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL31756551 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF3BRD4 | |
| Hydrochloric Acid SCHEMBL30720178 | 0.89 | CRBN (0.56) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL24421608 | 0.89 | CRBN (0.56) | CRBNDDB1IKZF3BRD4PARP1 | |
| Hydrochloric Acid SCHEMBL31759276 | 0.89 | CRBN (0.56) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL24671188 | 0.89 | CRBN (0.55) | CRBNDDB1IKZF3BRD4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | CRBN 929/4885DDB1 2514/4885IKZF3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.